Stora Södergatan 15
Lund 222 23
Sweden
https://www.wntresearch.com
版塊: Healthcare
行業: Biotechnology
全職員工: 2
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Thomas Andersson Ph.D. | Founder, Chief Scientific Officer, Director & Scientific Advisor | 572k | 無 | 1956 |
Dr. Per Goran Oskar Norlen | Chief Executive Officer | 無 | 無 | 1970 |
Mr. Anders Tidfors | Chief Financial Officer | 無 | 無 | 1964 |
Dr. Kicki Johansson | Chief Operating Officer | 無 | 無 | 1958 |
Mr. Dennis B. Henriksen M.Sc., Ph.D. | Chief Technical Officer | 418.81k | 無 | 1962 |
Mr. Klaus Christensen | Chief Commercial Officer | 無 | 無 | 1968 |
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer. The company was incorporated in 2007 and is based in Lund, Sweden.
截至 無 止,WntResearch AB 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。